» Articles » PMID: 34936028

Contingent Intramuscular Boosting of P2XR7 Axis Improves Motor Function in Transgenic ALS Mice

Overview
Publisher Springer
Specialty Biology
Date 2021 Dec 22
PMID 34936028
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Amyotrophic lateral sclerosis is a fatal neurodegenerative disorder that leads to progressive degeneration of motor neurons and severe muscle atrophy without effective treatment. Most research on the disease has been focused on studying motor neurons and supporting cells of the central nervous system. Strikingly, the recent observations have suggested that morpho-functional alterations in skeletal muscle precede motor neuron degeneration, bolstering the interest in studying muscle tissue as a potential target for the delivery of therapies. We previously showed that the systemic administration of the P2XR7 agonist, 2'(3')-O-(4-benzoylbenzoyl) adenosine 5-triphosphate (BzATP), enhanced the metabolism and promoted the myogenesis of new fibres in the skeletal muscles of SOD1G93A mice. Here we further corroborated this evidence showing that intramuscular administration of BzATP improved the motor performance of ALS mice by enhancing satellite cells and the muscle pro-regenerative activity of infiltrating macrophages. The preservation of the skeletal muscle retrogradely propagated along with the motor unit, suggesting that backward signalling from the muscle could impinge on motor neuron death. In addition to providing the basis for a suitable adjunct multisystem therapeutic approach in ALS, these data point out that the muscle should be at the centre of ALS research as a target tissue to address novel therapies in combination with those oriented to the CNS.

Citing Articles

Therapeutics Targeting Skeletal Muscle in Amyotrophic Lateral Sclerosis.

Gao J, Sterling E, Hankin R, Sikal A, Yao Y Biomolecules. 2024; 14(7).

PMID: 39062592 PMC: 11275039. DOI: 10.3390/biom14070878.


Role and therapeutic targets of P2X7 receptors in neurodegenerative diseases.

Zheng H, Liu Q, Zhou S, Luo H, Zhang W Front Immunol. 2024; 15:1345625.

PMID: 38370420 PMC: 10869479. DOI: 10.3389/fimmu.2024.1345625.


Intramuscular IL-10 Administration Enhances the Activity of Myogenic Precursor Cells and Improves Motor Function in ALS Mouse Model.

Fabbrizio P, Margotta C, DAgostino J, Suanno G, Quetti L, Bendotti C Cells. 2023; 12(7).

PMID: 37048088 PMC: 10093513. DOI: 10.3390/cells12071016.

References
1.
Rodgers J, King K, Brett J, Cromie M, Charville G, Maguire K . mTORC1 controls the adaptive transition of quiescent stem cells from G0 to G(Alert). Nature. 2014; 510(7505):393-6. PMC: 4065227. DOI: 10.1038/nature13255. View

2.
Mitchell J, McGoldrick P, Vance C, Hortobagyi T, Sreedharan J, Rogelj B . Overexpression of human wild-type FUS causes progressive motor neuron degeneration in an age- and dose-dependent fashion. Acta Neuropathol. 2012; 125(2):273-88. PMC: 3549237. DOI: 10.1007/s00401-012-1043-z. View

3.
Bryer S, Fantuzzi G, van Rooijen N, Koh T . Urokinase-type plasminogen activator plays essential roles in macrophage chemotaxis and skeletal muscle regeneration. J Immunol. 2008; 180(2):1179-88. DOI: 10.4049/jimmunol.180.2.1179. View

4.
Jessen K, Mirsky R . The repair Schwann cell and its function in regenerating nerves. J Physiol. 2016; 594(13):3521-31. PMC: 4929314. DOI: 10.1113/JP270874. View

5.
Forcina L, Cosentino M, Musaro A . Mechanisms Regulating Muscle Regeneration: Insights into the Interrelated and Time-Dependent Phases of Tissue Healing. Cells. 2020; 9(5). PMC: 7290814. DOI: 10.3390/cells9051297. View